Interferon-alpha-Induced Changes in NODDI Predispose to the Development of Fatigue.
Brain
/ diagnostic imaging
Cytokines
/ blood
Depression
/ blood
Diffusion Magnetic Resonance Imaging
/ methods
Fatigue
/ blood
Female
Hepatitis C
/ blood
Humans
Immunologic Factors
/ adverse effects
Inflammation
/ blood
Interferon-alpha
/ adverse effects
Male
Middle Aged
Neurites
Prospective Studies
Treatment Outcome
cytokine
depression
diffusion MRI
fatigue
inflammation
Journal
Neuroscience
ISSN: 1873-7544
Titre abrégé: Neuroscience
Pays: United States
ID NLM: 7605074
Informations de publication
Date de publication:
01 04 2019
01 04 2019
Historique:
received:
31
07
2017
revised:
20
12
2017
accepted:
21
12
2017
pubmed:
3
1
2018
medline:
10
7
2019
entrez:
3
1
2018
Statut:
ppublish
Résumé
Interferon-alpha (IFN-α) is an important mediator of antiviral immune responses. It is also used clinically in the treatment of hepatitis-C infection. Though effective, IFN-α-based therapies can often impair mood, motivation and cognition, which when severe can appear indistinguishable from major depression. In susceptible patients, fatigue and motivational impairment emerge early and have been linked to changes in basal ganglia (striatal) metabolism, neurochemistry and microstructural integrity. Here we use neurite orientation dispersion and density imaging (NODDI) modeling of multi-shell diffusion MRI to investigate whether changes in orientation-dispersion index (ODI) or neurite density index (NDI) can predict the later emergence of IFN-α-induced fatigue. Eighteen patients initiating IFN-α-based treatment for hepatitis-C underwent diffusion MRI and blood sampling at baseline and 4 h after their first IFN-α injection. They were then followed up with regular psychological assessments for 12 weeks of treatment. IFN-α injection stimulated an acute inflammatory cytokine response and evoked acute fatigue that peaked between 4 and 12 weeks of treatment. Within the brain, IFN-α induced an acute increase in NDI in patients that experienced a simultaneous increase in IFN-α-induced fatigue but not in patients that did not. Acute changes in striatal microstructure additionally predicted the continued development of fatigue but not mood symptoms 4 and 8 weeks later into treatment. Our findings highlight the value of NODDI as a potential in vivo biomarker of the central effects of peripheral inflammation. We highlight the exquisite sensitivity of the striatum to IFN-α and further implicate striatal perturbation in IFN-α-induced fatigue.
Identifiants
pubmed: 29292074
pii: S0306-4522(17)30930-2
doi: 10.1016/j.neuroscience.2017.12.040
pmc: PMC6458994
pii:
doi:
Substances chimiques
Cytokines
0
Immunologic Factors
0
Interferon-alpha
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
111-117Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P008747/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 093881/Z/10/Z
Pays : United Kingdom
Informations de copyright
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Magn Reson Med. 2009 Mar;61(3):560-9
pubmed: 19097244
J Neuroimmunol. 1997 Jun;76(1-2):105-11
pubmed: 9184639
NMR Biomed. 2016 Jan;29(1):33-47
pubmed: 26615981
Nat Rev Immunol. 2009 Jun;9(6):429-39
pubmed: 19461673
Biol Psychiatry. 2016 Feb 15;79(4):320-8
pubmed: 26169252
Arch Gen Psychiatry. 2012 Oct;69(10):1044-53
pubmed: 23026954
Nat Rev Neurosci. 2008 Jan;9(1):46-56
pubmed: 18073775
Nat Rev Drug Discov. 2016 Apr;15(4):275-92
pubmed: 26794270
Proc Natl Acad Sci U S A. 2010 May 4;107(18):8446-51
pubmed: 20404151
Radiology. 1994 Aug;192(2):521-9
pubmed: 8029426
IEEE Eng Med Biol Mag. 2004 Sep-Oct;23(5):57-64
pubmed: 15565800
Neuropsychopharmacology. 2014 Jun;39(7):1777-85
pubmed: 24481242
Psychiatry Res. 2001 Dec 15;105(1-2):45-55
pubmed: 11740974
Ann Clin Transl Neurol. 2017 Aug 15;4(9):663-679
pubmed: 28904988
Biol Psychiatry. 2009 Sep 1;66(5):415-22
pubmed: 19409533
J Neurosci. 2004 Oct 27;24(43):9669-73
pubmed: 15509754
Annu Rev Immunol. 2005;23:275-306
pubmed: 15771572
N Engl J Med. 2001 Mar 29;344(13):961-6
pubmed: 11274622
Curr Top Behav Neurosci. 2017;31:221-248
pubmed: 27272069
Biol Psychiatry. 2015 Jul 1;78(1):49-57
pubmed: 25526971
Neuroimage. 2017 Feb 15;147:517-531
pubmed: 27903438
Brain Behav Immun. 2016 Aug;56:34-41
pubmed: 26732827
Mol Psychiatry. 2008 Mar;13(3):293-301
pubmed: 17486106
J Virol. 2005 Jul;79(13):8295-302
pubmed: 15956575
J Neurol Sci. 1988 Apr;84(2-3):201-8
pubmed: 2837539
Cell Metab. 2011 Dec 7;14(6):724-38
pubmed: 22152301
NMR Biomed. 2005 Aug;18(5):277-84
pubmed: 15948233
Neuroimage. 2012 Jan 16;59(2):1114-22
pubmed: 21983184
Neuroimage. 2012 Jul 16;61(4):1000-16
pubmed: 22484410
J Neurosci. 2010 Nov 10;30(45):15298-303
pubmed: 21068334
Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13319-24
pubmed: 16141324
Neuropsychopharmacology. 2002 May;26(5):643-52
pubmed: 11927189
Magn Reson Med. 2004 Mar;51(3):473-9
pubmed: 15004787
Neuropsychopharmacology. 2007 Nov;32(11):2384-92
pubmed: 17327884